Retatrutide
LY-3437943 • Triple Agonist (GLP-1/GIP/Glucagon) Peptide for Metabolic & Weight Management Research
Retatrutide (LY-3437943) is a novel synthetic 39-amino acid peptide designed as a triple receptor agonist targeting the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCGR) receptors. It represents an advancement over dual agonists like tirzepatide, with research showing potent effects on weight loss, glycemic control, and energy expenditure in preclinical and clinical studies.
Chemical and Structural Properties
Molecular Formula: C₁₈₇H₂₈₁N₄₃O₆₀ (approximate)
Molecular Weight: ~4091–4730 Da (depending on exact form)
Classification: Acylated single-chain triple agonist peptide
Retatrutide is engineered from a GIP backbone with amino acid substitutions (including Aib and α-methyl leucine) and a lipid moiety for extended half-life (~6 days), enabling once-weekly administration in research protocols.
Mechanism of Action
Retatrutide simultaneously activates three key receptors for synergistic metabolic effects:
- GLP-1 Receptor: Enhances insulin secretion, suppresses glucagon, slows gastric emptying, and promotes satiety.
- GIP Receptor: Improves insulin sensitivity and has complementary effects on energy balance (stronger agonism in humans).
- Glucagon Receptor: Increases energy expenditure, lipolysis, and fatty acid oxidation while supporting glycemic control.
- Overall Synergy: Combines appetite suppression, increased satiety, elevated energy expenditure, and improved metabolic efficiency for substantial weight and fat loss.
Potential Research Findings & Benefits (Preclinical/Clinical)
| Area | Observed Effects in Models |
|---|---|
| Weight Loss | Up to 17–24% body weight reduction over 48 weeks in obesity studies (dose-dependent). |
| Glycemic Control | Significant HbA1c reductions and improved insulin sensitivity. |
| Metabolic Health | Reduced liver fat, improved lipid profiles, and increased energy expenditure. |
| Appetite Regulation | Strong suppression of appetite and enhanced satiety via central and peripheral pathways. |
| Body Composition | Preferential fat mass reduction while preserving lean mass in research settings. |
Safety Profile & Limitations
Important: Clinical studies report a safety profile consistent with incretin-based therapies, with common side effects including gastrointestinal issues (nausea, vomiting, diarrhea) that are often transient. For laboratory/research use only. Long-term safety data continues to be collected.
Key Research Gaps
- Large-scale Phase 3 trials and long-term cardiovascular outcomes data are ongoing.
- Optimal dosing strategies, combination therapies, and effects in diverse populations require further study.
- Full mechanistic details of receptor balance and tissue-specific effects are areas of active research.
Reviews
There are no reviews yet.